Shikiar Asset Management Inc. Has $691,000 Stake in Honeywell International Inc. (HON)

Shikiar Asset Management Inc. lowered its position in Honeywell International Inc. (NYSE:HON) by 9.9% during the second quarter, Holdings Channel reports. The institutional investor owned 4,800 shares of the conglomerate’s stock after selling 525 shares during the quarter. Shikiar Asset Management Inc.’s holdings in Honeywell International were worth $691,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of HON. CX Institutional purchased a new stake in Honeywell International during the 2nd quarter worth approximately $100,000. Wagner Wealth Management LLC purchased a new stake in Honeywell International during the 4th quarter worth approximately $101,000. Well Done LLC purchased a new stake in Honeywell International during the 1st quarter worth approximately $103,000. Jolley Asset Management LLC purchased a new stake in Honeywell International during the 2nd quarter worth approximately $104,000. Finally, Bruderman Asset Management LLC purchased a new stake in Honeywell International during the 1st quarter worth approximately $114,000. 74.81% of the stock is currently owned by hedge funds and other institutional investors.

Get Honeywell International alerts:

Shares of Honeywell International opened at $155.90 on Friday, according to MarketBeat Ratings. The company has a quick ratio of 1.11, a current ratio of 1.38 and a debt-to-equity ratio of 0.70. Honeywell International Inc. has a 12 month low of $134.50 and a 12 month high of $165.13. The company has a market cap of $116.51 billion, a price-to-earnings ratio of 20.45, a price-to-earnings-growth ratio of 1.83 and a beta of 1.03.

Honeywell International (NYSE:HON) last announced its quarterly earnings data on Friday, July 20th. The conglomerate reported $2.12 EPS for the quarter, beating the consensus estimate of $2.01 by $0.11. Honeywell International had a net margin of 3.88% and a return on equity of 31.46%. The business had revenue of $10.92 billion during the quarter, compared to analysts’ expectations of $10.80 billion. During the same period in the previous year, the business posted $1.80 EPS. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. equities research analysts forecast that Honeywell International Inc. will post 8.14 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 7th. Shareholders of record on Friday, August 17th will be paid a dividend of $0.745 per share. This represents a $2.98 annualized dividend and a yield of 1.91%. The ex-dividend date is Thursday, August 16th. Honeywell International’s payout ratio is 41.91%.

In other Honeywell International news, Director Linnet F. Deily sold 3,066 shares of Honeywell International stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $158.12, for a total transaction of $484,795.92. Following the completion of the sale, the director now directly owns 11,787 shares in the company, valued at approximately $1,863,760.44. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Timothy O. Mahoney sold 114,489 shares of Honeywell International stock in a transaction that occurred on Friday, May 25th. The shares were sold at an average price of $150.20, for a total transaction of $17,196,247.80. Following the sale, the insider now owns 314,725 shares of the company’s stock, valued at $47,271,695. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 130,977 shares of company stock valued at $19,788,828. Company insiders own 1.33% of the company’s stock.

Several research firms have weighed in on HON. Stifel Nicolaus boosted their target price on shares of Honeywell International from $157.00 to $175.00 and gave the stock a “buy” rating in a research report on Monday, April 23rd. Barclays boosted their target price on shares of Honeywell International from $170.00 to $172.00 and gave the stock an “overweight” rating in a research report on Monday, April 23rd. Zacks Investment Research raised shares of Honeywell International from a “hold” rating to a “buy” rating and set a $169.00 target price on the stock in a research report on Monday, May 28th. ValuEngine raised shares of Honeywell International from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Oppenheimer dropped their target price on shares of Honeywell International from $180.00 to $172.00 and set an “outperform” rating on the stock in a research report on Monday, April 30th. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $170.41.

Honeywell International Profile

Honeywell International Inc operates as a diversified technology and manufacturing company worldwide. It operates through four segments: Aerospace; Home and Building Technologies; Performance Materials and Technologies; and Safety and Productivity Solutions. The Aerospace segment supplies products, software, and services for aircraft and vehicles that it sells to original equipment manufacturers and other customers in various markets, including air transport, regional, business and general aviation aircraft, airlines, aircraft operators, defense and space contractors, and automotive and truck manufacturers.

See Also: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding HON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Honeywell International Inc. (NYSE:HON).

Top Small Cap Stocks To Own Right Now

tags:CNR,ACHN,FCEL,PQ,

Zinc may not immediately come to mind as an important metal for the global economy, but its actually the fourth most common metal in use -�trailing only iron, aluminium and copper. That��s because zinc would�most commonly be used as an anti-corrosion agent and for galvanization (coating of iron or steel) plus for other�industrial purposes (e.g. used as pigments,�preservatives, propellants etc). Zinc�was�also one of the best performing metals in 2016 and the outlook remains strong due in part to a global supply deficit��� meaning there are opportunities in zinc even for small cap miners. �

This brings me to Kootenay Zinc Corp (OTCMKTS: KTNNF; CNSX: ZNK)�which is a Canadian mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") deposits. The Company is�presently targeting the Sully Property which�comprises 1,375 hectares located approximately 30 kilometres east of Kimberley, B.C., and overlies rocks of similar age and origin as those which host the world-class Sullivan deposit, owned by Teck Resources Ltd. Sullivan was discovered in 1892, and is known to be one of the largest SEDEX deposits in the world. Over its 100-year lifetime, Sullivan has produced approximately 150 million tonnes of ore, including approximately three hundred million ounces of silver, eight million tonnes of zinc and eight million tonnes of lead.�

Top Small Cap Stocks To Own Right Now: China Metro-Rural Holdings Limited(CNR)

Advisors' Opinion:

• [By Shane Hupp]

  Wall Street analysts expect that Canadian National Railway (NYSE:CNI) (TSE:CNR) will announce $1.02 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.06 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings per share of $1.00 in the same quarter last year, which would suggest a positive year over year growth rate of 2%. The company is expected to announce its next quarterly earnings results on Tuesday, July 24th.

• [By Shane Hupp]

  Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp cut its position in Canadian National Railway (NYSE:CNI) (TSE:CNR) by 21.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,956,400 shares of the transportation company’s stock after selling 522,300 shares during the period. Canadian National Railway accounts for about 1.7% of Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s investment portfolio, making the stock its 7th biggest position. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.27% of Canadian National Railway worth $184,215,000 at the end of the most recent reporting period.

• [By Joseph Griffin]

  Shares of Canadian National Railway (TSE:CNR) (NYSE:CNI) have been given an average recommendation of “Buy” by the eleven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is C$109.36.

• [By Stephan Byrd]

  Brokerages expect Canadian National Railway (NYSE:CNI) (TSE:CNR) to announce earnings of $1.03 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.10 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings of $1.00 per share in the same quarter last year, which would indicate a positive year over year growth rate of 3%. The business is scheduled to issue its next quarterly earnings report on Tuesday, July 24th.

• [By Max Byerly]

  Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

• [By Max Byerly]

  Compass Capital Management Inc. bought a new position in Canadian National Railway (NYSE:CNI) (TSE:CNR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,535 shares of the transportation company’s stock, valued at approximately $207,000.

Top Small Cap Stocks To Own Right Now: Achillion Pharmaceuticals Inc.(ACHN)

Advisors' Opinion:

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Shane Hupp]

  News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.941587509483 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

• [By Ethan Ryder]

  Achillion Pharmaceuticals (NASDAQ:ACHN) – Research analysts at B. Riley reduced their FY2018 EPS estimates for shares of Achillion Pharmaceuticals in a research note issued to investors on Wednesday, May 2nd. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will earn ($0.58) per share for the year, down from their previous estimate of ($0.55). B. Riley has a “Neutral” rating and a $3.50 price objective on the stock. B. Riley also issued estimates for Achillion Pharmaceuticals’ FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($0.71) EPS, FY2021 earnings at ($0.70) EPS and FY2022 earnings at ($0.84) EPS.

Top Small Cap Stocks To Own Right Now: FuelCell Energy Inc.(FCEL)

Advisors' Opinion:

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on FuelCell Energy (FCEL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Paul Ausick]

  FuelCell Energy Inc. (NASDAQ: FCEL) posted an increase of 8% in short interest during the two-week period. Some 7.45 million shares were short as of May 31. The stock’s price was $1.76 at Monday’s market close, a spike of about 1.1% for the day, within a 52-week range of $1.08 to $2.49. Shares traded up about 2.5% in the two-week short interest period, and the number of days to cover rose from 14 to 17.

• [By Logan Wallace]

  FuelCell Energy (NASDAQ: FCEL) and HRG Group (NYSE:HRG) are both oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

• [By Paul Ausick]

  FuelCell Energy Inc. (NASDAQ: FCEL) posted a decrease of 25.7% in short interest during the period. Some 5.86 million shares were short as of April 30. The stock closed at $1.93 on Wednesday, up about 1.6% for the day, in a 52-week range of $0.80 to $2.49. Shares traded down about 7.8% in the short interest period, and days to cover rose from six to eight.

Top Small Cap Stocks To Own Right Now: Petroquest Energy Inc(PQ)

Advisors' Opinion:

• [By Ethan Ryder]

  News headlines about Petroquest Energy (NYSE:PQ) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Petroquest Energy earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the energy company an impact score of 47.638327846877 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Will Colgate-Palmolive Announce a Growth Rebound This Week?

The consumer staples industry has been hampered by slow growth and rising costs that companies are struggling to pass along to consumers. Colgate Palmolive�(NYSE:CL) hasn't proven itself to be immune from these challenges. In fact, the market share leader in toothpaste and toothbrushes lowered its sales outlook last quarter, which helped the stock underperform the broader market through the first half of 2018.

Colgate has a chance to shift that dynamic when it posts second-quarter results on Friday, July 27. However, investors aren't expecting dramatic improvements in its operating trends.

Image source: Getty Images.

Market share checkup

Colgate managed to accelerate sales growth up to 2% at the end of fiscal year 2017. Yet that success didn't carry over into the current year. Instead, sales inched higher by just 1.5% in the first quarter to trail management's expectations.

CEO Ian Cook said the period was "a challenging one as category growth remained soft in many markets around the world." Executives highlighted healthy volume gains in developed markets like the United States and Europe, but said emerging markets were much weaker.

The good news is, despite tough sales conditions in the industry, executives expect sales gains to speed up over the next few quarters. Thus, investors will be looking for Colgate to announce better organic growth results than its most recent 1.5% uptick.

The company will also update investors on its market share position, which should stay strong. At its last check-in Colgate revealed that it controlled 43.3% of the global toothpaste market and 32.6% of worldwide sales of manual toothbrushes.

Costs and prices

Faster growth might come at a price, though. For Colgate, this trade-off would show up in two key places. First, keep an eye on gross profit margin, which ticked down to 60.2% of sales from 60.3% last quarter. That figure isn't likely to rebound without stronger pricing trends than the flat result investors saw in the first quarter. If Colgate can't pass along rising raw material prices to its customers, then management's cost cutting efforts won't do much more than limit profitability declines.

Second, investors should watch for changes in operating profit margin, which will reflect the company's stepped-up advertising and marketing commitments. That metric dipped to 25.2% last quarter from 25.4% as the company boosted ad spending by 4% to $416 million. Cook said management plans to continue that marketing effort so that, with help from innovative product launches, sales growth trends will improve over the next few quarters.

Updated forecast

Finally, watch for an updated 2018 outlook that reflects the latest sales and profit trends. That forecast received a minor downgrade on both the top and bottom lines in late April. Regarding sales growth, management said they see organic revenue rising in the low single-digits whereas the prior forecast left open the possibility for mid-single-digit gains.

On profits, executives predicted low double-digit growth in per-share earnings for a slight decrease from their late January prediction. While it's possible that the 2018 forecast will rise due to a rebound in demand, the more likely scenario involves a steady, or even slightly deteriorating, outlook that follows the weak trends in the broader industry. As usual, investors can expect the earnings pinch to be muted this year, thanks to Colgate's dominant market position and its rock-solid finances.

Fox Run Management L.L.C. Invests $588,000 in Edwards Lifesciences Corp (EW) Stock

Fox Run Management L.L.C. bought a new stake in Edwards Lifesciences Corp (NYSE:EW) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,039 shares of the medical research company’s stock, valued at approximately $588,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Wendell David Associates Inc. raised its stake in Edwards Lifesciences by 4.0% in the 2nd quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after purchasing an additional 363 shares during the last quarter. IHT Wealth Management LLC grew its holdings in Edwards Lifesciences by 84.6% in the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock valued at $126,000 after buying an additional 427 shares during the period. Gulf International Bank UK Ltd grew its holdings in Edwards Lifesciences by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 66,330 shares of the medical research company’s stock valued at $9,254,000 after buying an additional 450 shares during the period. Daiwa Securities Group Inc. grew its holdings in Edwards Lifesciences by 9.1% in the 1st quarter. Daiwa Securities Group Inc. now owns 6,891 shares of the medical research company’s stock valued at $961,000 after buying an additional 572 shares during the period. Finally, WealthPLAN Partners LLC grew its holdings in Edwards Lifesciences by 22.2% in the 1st quarter. WealthPLAN Partners LLC now owns 3,225 shares of the medical research company’s stock valued at $450,000 after buying an additional 585 shares during the period. 81.27% of the stock is owned by hedge funds and other institutional investors.

Get Edwards Lifesciences alerts:

Several analysts have commented on EW shares. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Saturday, July 14th. ValuEngine upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Tuesday, June 12th. SunTrust Banks restated a “buy” rating and issued a $180.00 price target on shares of Edwards Lifesciences in a report on Tuesday, April 10th. Sanford C. Bernstein started coverage on Edwards Lifesciences in a report on Wednesday, June 27th. They issued a “market perform” rating and a $165.00 price target for the company. Finally, Northland Securities cut Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 25th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $152.65.

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 9th. The stock was sold at an average price of $134.73, for a total value of $3,368,250.00. Following the completion of the transaction, the chief financial officer now owns 35,968 shares in the company, valued at approximately $4,845,968.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The stock was sold at an average price of $128.46, for a total value of $4,213,488.00. Following the completion of the transaction, the chief executive officer now owns 74,131 shares of the company’s stock, valued at approximately $9,522,868.26. The disclosure for this sale can be found here. Insiders have sold a total of 230,249 shares of company stock valued at $31,802,645 in the last quarter. Company insiders own 1.84% of the company’s stock.

Shares of NYSE:EW opened at $152.62 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.07 and a quick ratio of 1.63. Edwards Lifesciences Corp has a 1 year low of $100.20 and a 1 year high of $155.22. The stock has a market cap of $31.68 billion, a PE ratio of 36.83, a PEG ratio of 2.20 and a beta of 0.64.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. The business had revenue of $938.00 million during the quarter, compared to analysts’ expectations of $936.69 million. During the same quarter in the previous year, the business earned $0.94 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. sell-side analysts forecast that Edwards Lifesciences Corp will post 4.63 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Here's What Every Investor Needs to Know About the Next Six Months

William Patalon III

A decade has passed since I first met�our Chief Investment Strategist Keith Fitz-Gerald�– and from that first day, the big-payoff investing ideas have just kept rolling in.

So I invited Keith to share his best ideas – and best strategies – for the last six months of 2018. It's going to be a challenging stretch – with unforeseen "wild cards" roiling already-turbulent waters.

He shared some incredible stock recommendations. He also offered one of the simplest – but most profound – bits of advice about surviving and thriving in the second half of this year. In fact, I'll share it before we get started:

"Right, now, BP, with all the wild cards, with all the uncertainty, with all the worries folks have – I still don't see this as a time to cut and run," said Keith.

He went on, "To me, the stock market at this time is about playing to strengths – and�not�bowing down to weaknesses. It's about being tactically opportunistic – and�not�'hunkering down.' I say all this for one very good reason: Threats and opportunities are just different sides of the same coin. It's all about how you look at things."

That's a "winner's way" of looking at things, as evidenced by the long list of double- and triple-digit winning stocks he's researched and recommended for his Money Map Report and High Velocity Profits subscribers in the first half of 2018.

Here's how he plans to build on that success in the months ahead…

Join the conversation. Click here to jump to comments…

William Patalon III

About the Author

Browse William's articles | View William's research services

Before he moved into the investment-research business in 2005, William (Bill) Patalon III spent 22 years as an award-winning financial reporter, columnist, and editor. Today he is the Executive Editor and Senior Research Analyst for Money Morning. With his latest project, Private Briefing, Bill takes you "behind the scenes" of his established investment news website for a closer look at the action. Members get all the expert analysis and exclusive scoops he can't publish... and some of the most valuable picks that turn up in Bill's closed-door sessions with editors and experts.

… Read full bio

Ideal Power (IPWR) Downgraded by Zacks Investment Research

Ideal Power (NASDAQ:IPWR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Ideal Power, Inc. is engaged in development of a novel, patented power conversion technology called Power Packet Switching Architecture(TM). The company also provides photovoltaic inverters and battery converters for grid storage and electrified vehicle fast-charging infrastructure. In addition, it offers hybrid power conversion systems and power switches. Ideal Power, Inc. is based in Spicewood, Texas. “

Get Ideal Power alerts:

A number of other equities research analysts have also weighed in on the stock. ValuEngine upgraded shares of Ideal Power from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. B. Riley restated a “hold” rating on shares of Ideal Power in a research note on Monday, May 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $2.19.

Shares of IPWR opened at $0.96 on Wednesday. The firm has a market cap of $14.42 million, a price-to-earnings ratio of -1.23 and a beta of 1.11. Ideal Power has a 1-year low of $0.92 and a 1-year high of $3.29.

Ideal Power (NASDAQ:IPWR) last announced its earnings results on Thursday, May 10th. The industrial products company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.32 million. Ideal Power had a negative net margin of 833.16% and a negative return on equity of 75.12%. equities research analysts predict that Ideal Power will post -0.56 earnings per share for the current year.

Ideal Power Company Profile

Ideal Power Inc develops power conversion solutions with a focus on solar and storage, microgrid, and stand-alone energy storage applications. It operates through two Divisions, Power Conversion Systems and B-TRAN. The Power Conversion Systems Division focuses on its Power Packet Switching Architecture technology.

Featured Article: What does RSI mean?

Get a free copy of the Zacks research report on Ideal Power (IPWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Mahindra CIE Q1 PAT seen up 45.5% YoY to Rs. 125.6 cr: ICICI Direct

ICICI Direct has come out with its first quarter (April-June�� 18) earnings estimates for the Automobiles sector. The brokerage house expects Mahindra CIE to report net profit at Rs. 125.6 crore up 45.5% year-on-year (up 7.9% quarter-on-quarter).

Net Sales are expected to increase by 17.4 percent Y-o-Y (down 1.5 percent Q-o-Q) to Rs. 1,772.6 crore, according to ICICI Direct.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 23.9 percent Y-o-Y (up 4.4 percent Q-o-Q) to Rs. 255 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Jul 18, 2018 12:46 pm

ResTORbio Bounces Back: Is the Biotech Stock a Buy?

ResTORbio, Inc. (NASDAQ:TORC) has had a fairly underwhelming start to public trading. The company completed its IPO earlier this year with an offering price of $15/share. TORC stock came out of the gate successfully, opening trading around the $18/share level. After hitting $21, however, things went south for resTORbio.

By April, TORC stock had fallen to below $8, losing half of its IPO value. Since then, resTORbio has seen a series of ups and downs. The stock hit $12 in May, fell back to the $8s, hit $12 again in June, and recently found itself back at $8. However, on Wednesday, resTORbio put in a sharp bounce, with shares rallying more than 10% off that support level. What reawakened TORC stock, and will it lead to further gains going forward?

What Is resTORbio Trying To Achieve?

As you might guess from the company’s capitalization of “TOR” and its ticker symbol, TOR is an important concept for the company. In particular, it stands for mTOR, a gene that is closely tied to aging in both mammals in general and humans specifically.

Needless to say, this genetic pathway could be a huge deal for medical research. The company’s name hints at restoration. A drug company that could tinker with the genes tied to aging could potentially make a fortune. mTOR drug inhibitors have been shown to extend the lifespans of mice. A similar finding, if it were to occur in humans, would be ground-breaking. mTOR also appears to be linked to cancers, and perhaps Alzheimer’s, autism, and other brain dysfunctions.

For now, however, resTORbio is starting off with more modest ambitions. The company’s main drug candidate, RTB101, focuses on lowering the number of respiratory tract infections that older people experience. RTIs are a major problem for people above the age of 65, leading to frequent hospitalizations.

In the company’s prospectus, they show Phase IIa data demonstrating that their drug appears to lower RTI occurrences around 40% or so compared to the placebo. If that result holds through more rigorous testing, it would be a major development, as RTIs are a large problem and thus the potential market could be vast.

What Happened This Week

TORC stock popped on Wednesday following a company press release highlighting more clinical data for their main drug. Their press release started off with the following news:

“resTORbio today announced newly published data from a Phase 2a clinical trial demonstrating that target of rapamycin complex 1 (TORC1) inhibitor treatment improved immune function and decreased incidence of all infections, including respiratory tract infections (RTIs), in people aged 65 years and older. RTIs in particular are a significant health risk for the elderly with life-threatening consequences and few treatment options. Data were published in the July 11, 2018 online edition of the journal Science Translational Medicine.”

The press release goes on to detail said finds from the study. It’s worth noting, however, that this data is not all that dissimilar to data that the company reported in its prospectus, though it does reaffirm those numbers.

This wasn’t the big catalyst that investors were waiting for, as we can see with the relatively muted response in the price of TORC stock. Instead, investors are looking forward to data readouts from the company’s Phase IIb trial which is expected in the first part of 2019. The company is running an additional trial with older and more at-risk folks, such as those with diabetes. If the drug shows similar efficacy in this higher stakes setting, it’d do a lot to increase the drug’s commercial prospects.

How Long Is Their Runway?

One of the pivotal questions for a clinical-stage biotech company is how long their cash will last. Since a biotech company with no approved drugs has minimal revenues, its cash position is of utmost importance.

Compare Brokers

In the case of resTORbio, the company had $135.7 million in cash at the end of March. That seems like a meaty cash position, given that the company only had a net loss of $41 million last year. However, the company is ramping up its spending post-IPO to power through its clinical trials. As a result, the company states that it has enough cash to last at least 12 months. But a capital raise later in 2019 wouldn’t be surprising.

For TORC stock, a key question will be when the company seeks to raise more money. The pivotal data readout is supposed to come in early 2019 with the Phase IIb trial results. If the drug shows strong efficacy, TORC stock should surge, making a capital raise significantly less dilutive. On the other hand, weak data would likely tank the stock. That’s especially true since resTORbio’s doesn’t have that much else in the clinical pipeline.

TORC Stock Verdict

As is often the case with clinical-stage biotech companies, this is a high-risk, high-reward venture. Even if the clinical data from the Phase IIb trial is good, resTORbio would still have to make it through Phase III, where many previously promising drugs end up failing to demonstrate statistical efficacy. It will still be a couple of years before resTORbio could potentially have an approved drug, meaning that the company will be reliant on the capital markets for funding. These ingredients make for a volatile stock price in the interim.

Additionally, it’s worth considering that resTORbio got access to this drug platform due to Novartis AG (NYSE:NVS) unloading it for a modest financial consideration and some equity in the company. Novartis executed a similar move with the UK biotech firm Mereo several years ago, and that one hasn’t been a winner as of yet. As always, it’s worth asking why Novartis would let this drug candidate go if it felt highly of its prospects.

Long story short, as it goes with clinical-stage biotech companies, there is loads of upside potential here. But a bad trial result could send shares down 50% or more. If you like the platform, the stock looks interesting here bouncing off technical support. Keep position sizes appropriate, however, considering the significant downside risk.

At the time of this writing, the author had no positions in the aforementioned securities.

Legendary Investor Louis Navellier’s #1 Stock to Buy NOW

Louis Navellier — the investor the New York Times called an “icon” — just helped investors make 487% in the booming Chinese stock market … 408% in the medical device sector … 150% in Netflix … all in less than 2 years! Now, Louis is urging investors to get in on what may be the opportunity of a lifetime. By using a unique investment strategy called “The Master Key,” you could make hundreds of percent returns over the next few years. Click here to learn about the #1 stock recommendation from one of America

Why Glu Mobile Inc. Stock Gained 13.7% in June

What happened

Shares of Glu Moble�(NASDAQ:GLUU)�climbed 13.7% in June, according to data from�S&P Global Market Intelligence�.�The mobile-gaming company's share price has climbed roughly 80% year to date on indications that its turnaround effort is proceeding successfully.�

GLUU data by YCharts

Glu is aiming to improve player engagement and spending on its legacy titles such as�Kim Kardashian Hollywood, Covet Fashion, and Design Home while also launching new franchises -- and it's seen encouraging early results for recent release�MLB Tap Sports Baseball 2018. The stock also gained ground following favorable ratings coverage from Piper Jaffray.

Image source: Getty Images.

So what

Glu posted better-than-expected earnings results at the beginning of May, helping to push its share price roughly 29% higher in the month. The successful debut of MLB Tap Sports Baseball 2018 also added to its stock gains, and some of the momentum from those catalysts carried on through June.

On June 15, Piper Jaffray analyst Michael Olson initiated ratings coverage on the stock, issuing an "overweight" rating and setting a $7.50 price target -- representing roughly 20% upside at the time of the note's publication and the stock's price as of this writing.�Glu is a relatively small company with a market cap of roughly $850 million, so it's not unusual to see its valuation post significant gains following positive coverage from a highly regarded ratings firm.

Now what

Glu's valuation has seen some big swings since the company went public in 2007.

GLUU data by YCharts

Much of the volatility has been tied to shifts in the company's section of the gaming industry -- with the rise and fall of Facebook-based browser games and celebrity-focused titles being among the most notable changes to impact performance.

Glu has recently had success with its pivot away from celebrity-focused games, with 69% of its bookings in the March-ended quarter coming from original intellectual properties. However, there are still reasons to be cautious about the company's long-term prospects. The mobile-games space is highly competitive, and Glu will have to contend with more resource-rich competitors such as�Activision Blizzard, Electronic Arts, and Take-Two Interactive, as well as a wide range of smaller independent studios.

Despite favorable trends shaping the broader gaming industry, there's limited visibility on how the company's efforts to introduce new properties will fare -- so those considering buying Glu Mobile should proceed with the understanding that it's not a low-risk investment.

Funko Inc (FNKO) Expected to Announce Quarterly Sales of $122.76 Million

Equities research analysts expect Funko Inc (NASDAQ:FNKO) to post sales of $122.76 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Funko’s earnings, with the lowest sales estimate coming in at $117.10 million and the highest estimate coming in at $126.89 million. The business is scheduled to issue its next earnings report on Thursday, August 9th.

According to Zacks, analysts expect that Funko will report full-year sales of $614.80 million for the current financial year, with estimates ranging from $610.30 million to $626.61 million. For the next fiscal year, analysts forecast that the business will post sales of $694.25 million per share, with estimates ranging from $680.20 million to $712.36 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Funko.

Get Funko alerts:

Funko (NASDAQ:FNKO) last posted its quarterly earnings results on Thursday, May 10th. The company reported $0.04 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.05. The firm had revenue of $137.20 million during the quarter, compared to analyst estimates of $122.64 million. The company’s revenue for the quarter was up 38.4% compared to the same quarter last year.

Separately, Zacks Investment Research upgraded Funko from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Wednesday, July 4th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Funko presently has an average rating of “Buy” and an average target price of $12.67.

A number of hedge funds and other institutional investors have recently modified their holdings of FNKO. California Public Employees Retirement System bought a new position in Funko in the fourth quarter worth about $2,496,000. BlackRock Inc. bought a new position in Funko in the fourth quarter worth about $3,542,000. Allianz Asset Management GmbH bought a new position in Funko in the fourth quarter worth about $831,000. Geode Capital Management LLC bought a new position in Funko in the fourth quarter worth about $137,000. Finally, Deutsche Bank AG bought a new position in Funko in the fourth quarter worth about $157,000. 9.84% of the stock is currently owned by hedge funds and other institutional investors.

Funko opened at $13.82 on Tuesday, MarketBeat.com reports. The stock has a market capitalization of $718.40 million and a P/E ratio of 46.07. Funko has a one year low of $5.81 and a one year high of $15.16. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.63 and a quick ratio of 1.01.

Funko Company Profile

Funko, Inc, a pop culture consumer products company, designs, sources, and distributes licensed pop culture products in the United States, China, Vietnam, and the United Kingdom. The company offers vinyl, bobble head, blind-packed miniature, and action figures; and plush products, accessories, apparels, and homewares, as well as bags, purses, and wallets.

Get a free copy of the Zacks research report on Funko (FNKO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Safest Stocks To Own For 2019

tags:BCOV,CGI,DCT,CRT,

On the lookout for safe dividends? (Who isn’t, right?)

These days, you generally have three options: large-cap stocks with long dividend histories, municipal bonds and US Treasuries.

Treasuries are considered the safest of that group, and large-cap stocks the riskiest, but they’re still much safer than plenty of other investments, such as small caps and junk bonds.

I’ll show you two low-risk investments that are great buys now in a moment. But first, I want to tell you why recent events have called the safety of some of the options I just named into question.

Let’s start by looking at the following chart:

“Safe” Assets Turn Volatile

First, note how the iShares S&P National AMT-Free Municipal Bond Fund (MUB), a good proxy for municipal bonds as a whole, is the least volatile of the three funds shown above. But right now, it faces a steep downturn relative to its earlier stability.

Best Safest Stocks To Own For 2019: Brightcove Inc.(BCOV)

Advisors' Opinion:

• [By Stephan Byrd]

  These are some of the news headlines that may have effected Accern’s scoring:

  Get Brightcove alerts: Critical Analysis: Brightcove (BCOV) vs. Smartsheet (SMAR) (americanbankingnews.com) Brightcove (BCOV) PT Raised to $13.00 at Stifel Nicolaus (americanbankingnews.com) Brightcove Pushes the Envelope with Video Experiences that Increase Customer ROI (finance.yahoo.com) Brightcove Launches OTT Flow X, Powered by Accedo (finance.yahoo.com)

  A number of research analysts have recently issued reports on BCOV shares. Zacks Investment Research cut shares of Brightcove from a “buy” rating to a “hold” rating in a research note on Wednesday, April 25th. Dougherty & Co lifted their target price on shares of Brightcove from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 17th. BidaskClub upgraded shares of Brightcove from a “hold” rating to a “buy” rating in a research report on Saturday, April 28th. TheStreet upgraded shares of Brightcove from a “d+” rating to a “c-” rating in a research report on Monday, May 7th. Finally, Stifel Nicolaus boosted their price objective on shares of Brightcove from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $9.85.

Best Safest Stocks To Own For 2019: Celadon Group, Inc.(CGI)

Advisors' Opinion:

• [By Stephan Byrd]

  Russell Investments Group Ltd. boosted its position in shares of Celadon Group, Inc. (NYSE:CGI) by 26.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,347,089 shares of the transportation company’s stock after purchasing an additional 283,476 shares during the quarter. Russell Investments Group Ltd. owned about 4.76% of Celadon Group worth $4,983,000 as of its most recent filing with the Securities and Exchange Commission.

• [By Ethan Ryder]

  Scopus Asset Management L.P. reduced its holdings in shares of Celadon Group, Inc. (NYSE:CGI) by 57.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 900,000 shares of the transportation company’s stock after selling 1,218,285 shares during the quarter. Scopus Asset Management L.P. owned approximately 3.18% of Celadon Group worth $3,330,000 as of its most recent filing with the SEC.

Best Safest Stocks To Own For 2019: DCT Industrial Trust Inc(DCT)

Advisors' Opinion:

• [By Joseph Griffin]

  Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of DCT Industrial Trust Inc (NYSE:DCT) by 7.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,570 shares of the real estate investment trust’s stock after acquiring an additional 1,044 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in DCT Industrial Trust were worth $821,000 as of its most recent filing with the Securities and Exchange Commission.

• [By ]

  For an "Executive Decision" segment, Cramer spoke with Hamid Moghadam, chairman and CEO of the logistics REIT, Prologis Inc.  (PLD) , which recently announced the acquisition of DCT Industrial Trust (DCT) .

• [By Stephan Byrd]

  Teza Capital Management LLC bought a new stake in DCT Industrial Trust Inc (NYSE:DCT) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,379 shares of the real estate investment trust’s stock, valued at approximately $359,000.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on DCT Industrial Trust (DCT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Daiwa Securities Group Inc. lifted its holdings in DCT Industrial Trust Inc (NYSE:DCT) by 25.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 19,700 shares of the real estate investment trust’s stock after purchasing an additional 4,000 shares during the period. Daiwa Securities Group Inc.’s holdings in DCT Industrial Trust were worth $1,110,000 at the end of the most recent quarter.

Best Safest Stocks To Own For 2019: Cross Timbers Royalty Trust(CRT)

Advisors' Opinion:

• [By Ethan Ryder]

  News stories about Cross Timbers Royalty Trust (NYSE:CRT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cross Timbers Royalty Trust earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned headlines about the oil and gas company an impact score of 47.0297657024049 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Hot Dividend Stocks To Invest In 2019

tags:PTIE,ESLT,AUPH,

LSB Industries (NYSE: LXU) and Minerals Technologies (NYSE:MTX) are both multi-sector conglomerates companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Dividends

Get LSB Industries alerts:

Minerals Technologies pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. LSB Industries does not pay a dividend. Minerals Technologies pays out 4.4% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for LSB Industries and Minerals Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LSB Industries 0 0 0 0 N/A Minerals Technologies 0 1 0 0 2.00

Earnings & Valuation

Hot Dividend Stocks To Invest In 2019: Pain Therapeutics(PTIE)

Advisors' Opinion:

• [By Chris Lange]

  Pain Therapeutics Inc. (NASDAQ: PTIE) shares were destroyed on Wednesday after a vote from the U.S. Food and Drug Administration (FDA) was announced. As we have said before, the FDA has the potential to make or break biopharmaceutical companies. In this case, Pain Therapeutics has been broken.

• [By Lisa Levin] Gainers Blink Charging Co. (NASDAQ: BLNK) shares climbed 31.68 percent to close at $7.19 on Wednesday. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million. Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares gained 24.15 percent to close at $3.29. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share. 21Vianet Group, Inc. (NASDAQ: VNET) shares surged 24 percent to close at $6.82. Check-Cap Ltd. (NASDAQ: CHEK) gained 20.25 percent to close at $4.87. HUYA Inc. (NYSE: HUYA) shares surged 18.42 percent to close at $22.50 Abaxis, Inc. (NASDAQ: ABAX) rose 16.15 percent to close at $83.34. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash. Pain Therapeutics, Inc. (NASDAQ: PTIE) shares jumped 16.07 percent to close at $10.62. Bilibili Inc. (NASDAQ: BILI) rose 16.04 percent to close at $14.11. Gemphire Therapeutics Inc. (NASDAQ: GEMP) gained 14.88 percent to close at $6.33. Phoenix New Media Limited (NYSE: FENG) rose 13.96 percent to close at $5.55. Daqo New Energy Corp. (NYSE: DQ) jumped 13.88 percent to close at $67.27 on Wednesday. Sea Limited (NYSE: SE) jumped 12.59 percent to close at $11.98 after reporting Q1 results. Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 12.01 percent to close at $5.13. Ascena Retail Group, Inc. (NASDAQ: ASNA) gained 11.93 percent to close at $3.19. Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 11.66 percent to close at $24.52 on Wednesday after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. Macy's, Inc. (NYSE: M) rose 10.83 percent to close at $33.17 after the company reported stronger-than-expected results for its first quarter and lifted guidance. ChemoCentryx, Inc. (NASDAQ: CCXI) gained 9.36 percent to close at $12.50. Canaccord Genuity initiated coverage on ChemoCentryx with a Buy rating. Biolinerx Ltd/S ADR (NASDAQ: BLRX)
• [By Peter Graham]

  Small cap pain stock Pain Therapeutics (NASDAQ: PTIE) has elevated short interest of 35.77% according to Highshortinterest.com. Pain Therapeutics�develops proprietary drugs that offer significant improvements to patients and physicians.�The Company��s�expertise consists of developing new drugs and guiding these through various regulatory and development pathways in preparation for their eventual commercialization with a focus�on drug development efforts around disorders of the nervous system.�The FDA has not yet established the safety or efficacy of�any drug candidates. Pain Therapeutics���pipeline of drug assets includes:

• [By Brian Orelli]

  DURECT Corp. (NASDAQ:DRRX) is down 9.2% at 12:45 p.m. EDT after the U.S. Food and Drug Administration's advisory committee voted�14 to 3 recommending the agency not approve Remoxy ER, an abuse-deterrent extended-release pain medication being developed by its partner Pain Therapeutics�(NASDAQ: PTIE).

Hot Dividend Stocks To Invest In 2019: Elbit Systems Ltd.(ESLT)

Advisors' Opinion:

• [By Stephan Byrd]

  BidaskClub upgraded shares of Elbit Systems (NASDAQ:ESLT) from a sell rating to a hold rating in a report issued on Wednesday.

  Several other equities research analysts have also weighed in on the company. ValuEngine upgraded Elbit Systems from a hold rating to a buy rating in a report on Thursday, March 1st. TheStreet lowered Elbit Systems from a b rating to a c+ rating in a report on Tuesday, May 29th. Finally, Chardan Capital restated a neutral rating on shares of Elbit Systems in a report on Friday, June 1st. Five investment analysts have rated the stock with a hold rating, Elbit Systems presently has an average rating of Hold and an average price target of $176.00.

• [By Logan Wallace]

  Shares of Elbit Systems Ltd (NASDAQ:ESLT) have been given an average rating of “Hold” by the five research firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation.

• [By Lisa Levin] Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) rose 7.3 percent to $6.90 in pre-market trading after the company reported the FDA approval of TX-004HR: IMVEXXY (estradiol vaginal inserts) for moderate to severe dyspareunia due to menopause. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 6.1 percent to $10.50 in pre-market trading after falling 1.20 percent on Tuesday Movado Group, Inc. (NYSE: MOV) shares rose 5.7 percent to $44.60 in pre-market trading after the company reported better-than-expected Q1 results and raised its guidance. salesforce.com, inc. (NYSE: CRM) rose 5.4 percent to $133.67 in pre-market trading after the company reported better-than-expected earnings for its first quarter and raised its forecast for the full year. Sirius XM Holdings Inc. (NASDAQ: SIRI) rose 5.3 percent to $7.35 in pre-market trading. PagSeguro Digital Ltd. (NYSE: PAGS) rose 5.3 percent to $33.50 in pre-market trading after reporting Q1 results. SpartanNash Co (NASDAQ: SPTN) rose 4.9 percent to $19.80 in pre-market trading after the company reported upbeat earnings for its first quarter on Tuesday. Groupon, Inc. (NASDAQ: GRPN) rose 4.9 percent to $4.95 in pre-market trading. Dalian Wanda will set up a joint venture with Tencent and Groupon's former local unit, Reuters reported. Okta, Inc. (NASDAQ: OKTA) rose 4.4 percent to $56 in pre-market trading after gaining 3.43 percent on Tuesday Elbit Systems Ltd. (NASDAQ: ESLT) rose 4.3 percent to $120.92 in pre-market trading after gaining 2.05 percent on Tuesday. STMicroelectronics N.V. (NYSE: STM) shares rose 3.7 percent to $23.78 in pre-market trading after falling 4.70 percent on Tuesday. EVINE Live Inc (NASDAQ: EVLV) shares rose 2.7 percent to $1.14 in pre-market trading after reporting Q1 results.

  Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Hot Dividend Stocks To Invest In 2019: Aurinia Pharmaceuticals Inc(AUPH)

Advisors' Opinion:

• [By Logan Wallace]

  Isotechnika Pharma Inc. (NASDAQ:AUPH) (TSE:AUP) shares rose 6.7% during trading on Friday . The stock traded as high as $5.68 and last traded at $5.59. Approximately 54,590 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 429,596 shares. The stock had previously closed at $5.24.

• [By Keith Speights]

  That statement comes to mind when I think about Aurinia Pharmaceuticals (NASDAQ:AUPH). The potential for the clinical-stage biotech appears to be so great that getting greedy with the stock is tempting.�

• [By Cory Renauer]

  Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH),�a clinical-stage biotech, are on the rise following the company's first-quarter earnings report. Plans to expand voclosporin, the company's lupus candidate, to a much larger indication inspired investors to push the shares 10.2% higher as of 1:03 p.m. Monday.

Corporate Bond Issuance Decelerates to Its Slowest Pace This Year

LISTEN TO ARTICLE 1:43 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

Sales of investment-grade U.S. corporate bonds are on pace for the slowest week of the year as a flood of debt last week and trade tensions cool demand.

High-grade bond issuance is so far just 6 percent of the low-end projection of $15 billion for the week, and headed for the smallest amount since December, according to data compiled by Bloomberg. No borrowers stepped up on Monday or Wednesday, and Charter Communications Inc. was the only name to announce a deal Thursday.

The falloff in sales is more than just summer doldrums. Last week deals from Walmart Inc. and Bayer AG helped boost total issuance to the most since March at $44 billion. Trade tensions have also pushed investors to the safety of Treasuries, driving the 10-year yield to the lowest since May on Wednesday.

“I think they likely jammed too much supply through last week, and some digestion has to take place, which puts pressure on secondary spreads,” said Scott Kimball, portfolio manager at BMO Global Asset Management in Miami. “But more importantly, there has been a significant decline in U.S. benchmark Treasury yields.”

M&A Mania Grips High-Grade Bond Sales

Top five acquisition financing transactions have accounted for $90 billion

Bloomberg

.chart-js { display: none; }

Lower yields are good for corporate borrowers, “but from the buyer’s perspective, people are concerned about rates and duration-sensitive credit, which is what IG is,” Kimball said.

The secondary market is also under pressure. The Bloomberg Barclays benchmark investment-grade bond index is at the widest level since December 2016, while the cost to buy protection has risen to the highest since March.

#lazy-img-328933474:before{padding-top:56.25%;}

The largest supply has already come and gone, Bank of America said in a recent note. United Technologies Corp. is the only large deal expected this summer and second-quarter earnings season will keep some companies on the sideline, allowing spreads to tighten.

— With assistance by Brian W Smith, and Adam Tempkin

Casella Waste Systems (CWST) Upgraded at BidaskClub

BidaskClub upgraded shares of Casella Waste Systems (NASDAQ:CWST) from a hold rating to a buy rating in a report published on Wednesday morning.

A number of other brokerages have also recently weighed in on CWST. Zacks Investment Research upgraded Casella Waste Systems from a hold rating to a buy rating and set a $29.00 price target for the company in a research report on Thursday, February 22nd. TheStreet upgraded Casella Waste Systems from a d rating to a c rating in a research report on Thursday, March 1st. ValuEngine upgraded Casella Waste Systems from a hold rating to a buy rating in a research report on Wednesday, March 7th. Finally, UBS Group assumed coverage on Casella Waste Systems in a research report on Wednesday, March 14th. They issued a neutral rating and a $25.00 price target for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $27.33.

Get Casella Waste Systems alerts:

Shares of Casella Waste Systems opened at $26.51 on Wednesday, MarketBeat reports. Casella Waste Systems has a fifty-two week low of $15.20 and a fifty-two week high of $27.50. The firm has a market capitalization of $1.13 billion, a PE ratio of 40.00 and a beta of 0.93. The company has a debt-to-equity ratio of -12.75, a current ratio of 1.00 and a quick ratio of 0.93.

Casella Waste Systems (NASDAQ:CWST) last announced its quarterly earnings results on Thursday, May 3rd. The industrial products company reported $0.00 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.01. Casella Waste Systems had a negative return on equity of 53.97% and a negative net margin of 4.16%. The business had revenue of $147.50 million during the quarter, compared to analysts’ expectations of $139.13 million. During the same quarter last year, the business posted ($0.01) earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. sell-side analysts anticipate that Casella Waste Systems will post 0.71 earnings per share for the current fiscal year.

In related news, CFO Edmond Coletta sold 33,000 shares of the stock in a transaction on Thursday, May 24th. The stock was sold at an average price of $23.79, for a total transaction of $785,070.00. Following the sale, the chief financial officer now owns 117,255 shares of the company’s stock, valued at $2,789,496.45. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Christopher Heald sold 4,000 shares of the stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $24.56, for a total value of $98,240.00. Following the sale, the vice president now directly owns 89,484 shares in the company, valued at approximately $2,197,727.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 73,354 shares of company stock worth $1,761,331. Corporate insiders own 11.47% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ramsey Quantitative Systems acquired a new stake in shares of Casella Waste Systems during the fourth quarter valued at $123,000. SG Americas Securities LLC acquired a new stake in shares of Casella Waste Systems during the first quarter valued at $142,000. Aperio Group LLC acquired a new stake in shares of Casella Waste Systems during the fourth quarter valued at $231,000. Citigroup Inc. boosted its stake in shares of Casella Waste Systems by 417.9% during the first quarter. Citigroup Inc. now owns 10,643 shares of the industrial products company’s stock valued at $249,000 after acquiring an additional 8,588 shares during the last quarter. Finally, Stone Ridge Asset Management LLC acquired a new stake in shares of Casella Waste Systems during the fourth quarter valued at $263,000. 83.10% of the stock is currently owned by institutional investors and hedge funds.

About Casella Waste Systems

Casella Waste Systems, Inc, together with its subsidiaries, operates as a vertically-integrated solid waste services company in the northeastern United States. The company operates through Eastern Region, Western Region, Recycling, and Other segments. It offers resource management services primarily in the areas of solid waste collection and disposal, transfer, recycling, and organics services to residential, commercial, municipal, and industrial customers.

Here��s Why You Shouldn��t Fear a Trade War

The Dow Jones took its eighth consecutive licking yesterday �� its worst streak since last March.

Down too was the S&P�� and the Nasdaq.

VIX, Wall Street��s ��fear gauge,�� was in panicked spasm.

For the explanation, we turn to CNBC:

��Dow drops about 200 points on trade worries, extends losing streak to eight days.��

It is the trade wars �� again.

Trade-sensitive stocks such as Boeing and Caterpillar took the heaviest rattling yesterday.

“The focus has been back on tariffs,” confirms Michael Hans, CIO of Clarfeld Financial Advisors.

Meantime, Goldman Sachs thinks “further escalation seems likely.”

But in the face of trade upheaval, where can the smart investor find refuge?

Gold, perhaps�� or maybe Treasuries?

Or something else altogether?

We put our agents on the case:

��Go find us an investment that will advantage our readers while trade war hammers the markets!��

Dutifully, they soon reported a beacon of light�� an investment class that has soared as trade war fears shake the overall market.

��While the U.S. and China are embroiled in an escalating trade war,�� affirms ETF Trends, this investment is ��outperforming.��

It is ��mostly immune to any external shocks,�� says Zacks.

Indeed��

While the Dow Jones has lost 0.8% on the year…

And while the S&P has eked out a slender 3.1% gain, this investment class has surged as much as 13.2%.

In fact, it tallied an all-time high on Wednesday�� while the overall market sank in trade-filled despair.

The asset under discussion is not gold. Or Treasuries.

Then what?

The answer is… small-cap stocks.

Small-cap stocks are the antidote to trade-war fever.

The iShares Core S&P Small-Cap ETF �� which tracks the S&P Small-Cap 600 index �� is up 13.2% this year.

Meantime, the iShares Russell 2000 ETF �� which does duty for the small-cap Russell 2000 �� is up 11.8%.

The Russell 2000 has registered 23 record highs this year�� even as the overall market ��corrected�� 11% in February.

Interesting, you say.

But why are these small fry doing circles around the Dow Jones and the S&P?

The answer begins with the dollar.

We must first look to the stronger dollar…

Large U.S. multinationals earn vast revenues overseas �� but they are earning these in weaker currencies.

When they convert these revenues from softer currencies to stronger dollars�� the conversion leaves them short.

Their dollar earnings are depressed.

And according to FactSet, S&P 500 companies earn 38% of their income abroad.

On the other hand�� S&P Small Cap 600 businesses only generate some 20% from overseas sales.

Thus, much of their earnings arrive in stronger dollars.

Thus their greater earnings.

Thus their greater investor appeal.

��We continue to like small-cap equities because they have a more domestic focus, [and are] less impacted by trade or dollar fluctuations,�� explains Angus Sippe, fund manager at Schroders.

��Smaller companies have some natural hedges against risks like trade,�� adds Tim Courtney, CIO at Exencial Wealth Advisors.

Meantime, official numbers indicate strong retail and consumer spending trends �� rightly or wrongly.

And the National Federation of Independent Business reports small-business profits have notched their highest reading since records began in 1973.

This pleasant fact they attribute to the Trump tax cuts.

In summary, concludes Ryan Crane, CIO of Stephens Investment Management Group:

Small caps are being favored because they��re less exposed to foreign markets, and because they don��t have currency issues, which is becoming a problem for bigger names. Also, they should derive a disproportionate benefit from the tax bill, because the larger firms have big teams that were already working to minimize their tax burdens, so lower rates will mean less for them.

And so we rest our case on behalf of the small-cap stock.

Our default setting is one of detached indifference �� we are observers, not drummers.

And detached observers we remain.

But if you wish to hunt big game right now�� it appears you may wish to think small…

Regards,

Brian Maher
Managing editor, The Daily Reckoning

RPX (RPXC) Raised to Sell at BidaskClub

RPX (NASDAQ:RPXC) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday.

RPXC has been the subject of several other research reports. TheStreet downgraded RPX from a “b-” rating to a “c-” rating in a research note on Thursday, February 22nd. ValuEngine downgraded RPX from a “hold” rating to a “sell” rating in a research note on Saturday, May 12th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the stock. RPX currently has a consensus rating of “Hold” and a consensus target price of $14.33.

Get RPX alerts:

Shares of NASDAQ RPXC opened at $10.48 on Wednesday. The stock has a market cap of $523.31 million, a price-to-earnings ratio of 22.78 and a beta of 1.29. RPX has a 12 month low of $9.74 and a 12 month high of $14.99.

RPX (NASDAQ:RPXC) last issued its earnings results on Tuesday, May 1st. The business services provider reported $0.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.17 by ($0.07). The business had revenue of $67.10 million for the quarter, compared to analyst estimates of $73.50 million. RPX had a positive return on equity of 5.04% and a negative net margin of 27.00%. The firm’s revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.19 EPS.

Hedge funds and other institutional investors have recently modified their holdings of the business. AMP Capital Investors Ltd acquired a new position in RPX during the fourth quarter worth about $144,000. Royal Bank of Canada grew its holdings in shares of RPX by 53.1% during the first quarter. Royal Bank of Canada now owns 15,310 shares of the business services provider’s stock worth $163,000 after purchasing an additional 5,310 shares during the last quarter. Martingale Asset Management L P bought a new stake in shares of RPX during the fourth quarter worth about $169,000. Capital Fund Management S.A. bought a new stake in shares of RPX during the fourth quarter worth about $171,000. Finally, Wedge Capital Management L L P NC bought a new stake in shares of RPX during the first quarter worth about $178,000. 88.84% of the stock is owned by hedge funds and other institutional investors.

About RPX

RPX Corporation provides patent risk management and discovery services in the United States, Japan, South Korea, and internationally. It offers a subscription-based patent risk management service that facilitates exchanges of value between owners and users of patents. The company also provides a defensive patent aggregation in which it acquires patent assets to offer clients with sub-licenses; and underwrites patent infringement liability insurance policies to insure against certain costs of litigation.

Northrim BanCorp (NRIM) versus Hometrust Bancshares (HTBI) Financial Analysis

Northrim BanCorp (NASDAQ: NRIM) and Hometrust Bancshares (NASDAQ:HTBI) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

Get Northrim BanCorp alerts:

This is a summary of current recommendations and price targets for Northrim BanCorp and Hometrust Bancshares, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Northrim BanCorp	0	0	0	0	N/A
Hometrust Bancshares	0	2	0	0	2.00

Hometrust Bancshares has a consensus price target of $27.50, suggesting a potential upside of 2.04%. Given Hometrust Bancshares’ higher possible upside, analysts plainly believe Hometrust Bancshares is more favorable than Northrim BanCorp.

Earnings and Valuation

This table compares Northrim BanCorp and Hometrust Bancshares’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northrim BanCorp	$100.58 million	2.71	$13.15 million	$2.04	19.46
Hometrust Bancshares	$114.88 million	4.47	$11.72 million	$0.94	28.67

Northrim BanCorp has higher earnings, but lower revenue than Hometrust Bancshares. Northrim BanCorp is trading at a lower price-to-earnings ratio than Hometrust Bancshares, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Northrim BanCorp and Hometrust Bancshares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northrim BanCorp	13.47%	8.45%	1.08%
Hometrust Bancshares	4.40%	5.97%	0.74%

Volatility & Risk

Northrim BanCorp has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Hometrust Bancshares has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Dividends

Northrim BanCorp pays an annual dividend of $0.96 per share and has a dividend yield of 2.4%. Hometrust Bancshares does not pay a dividend. Northrim BanCorp pays out 47.1% of its earnings in the form of a dividend.

Insider & Institutional Ownership

70.7% of Northrim BanCorp shares are held by institutional investors. Comparatively, 60.6% of Hometrust Bancshares shares are held by institutional investors. 2.9% of Northrim BanCorp shares are held by insiders. Comparatively, 6.3% of Hometrust Bancshares shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Northrim BanCorp beats Hometrust Bancshares on 8 of the 14 factors compared between the two stocks.

About Northrim BanCorp

Northrim BanCorp, Inc. operates as the bank holding company for Northrim Bank that provides commercial banking products and services to businesses and professionals in Alaska. The company operates in two segments, Community Banking and Home Mortgage Lending. It offers various deposit products, including noninterest-bearing checking accounts and interest-bearing time deposits, checking accounts, and savings accounts, as well as money market deposit accounts, certificates of deposit, and courier noncash deposits. The company also provides family residential mortgages; commercial loans, such as secured and unsecured loans for working capital and expansion; commercial real estate loans; construction loans for commercial real estate projects, and land development and residential subdivision construction loans; and consumer loans comprising loans for automobiles, recreational vehicles, boats, and other consumer purchases, as well as home equity and commercial credit lines, and factoring services. In addition, it offers other services comprising consumer online banking, mobile app and mobile deposit, mobile Web and text banking, business online banking, personal finance, online documents, consumer and business debit cards, personalized checks at account opening, telebanking, automated teller, overdraft protection from a savings account, commercial drive-up banking, automatic transfers and payments, wire transfers, direct payroll deposit, electronic tax payments, automated clearing house origination and receipt, remote deposit capture, merchant, and cash management services, as well as annuity products, and long term investment portfolios. As of January 29, 2018, the company operated 14 branches in Anchorage, the Matanuska Valley, Juneau, Fairbanks, Ketchikan, and Sitka. Northrim BanCorp, Inc. was founded in 1990 and is headquartered in Anchorage, Alaska.

About Hometrust Bancshares

HomeTrust Bancshares, Inc. operates as the bank holding company for HomeTrust Bank that provides a range of retail and commercial banking products. Its deposit products consist of savings, money market, and demand accounts, as well as certificates of deposit for individuals, businesses, and nonprofit organizations. The company's loan portfolio comprises retail consumer loans, such as one-to-four-family residential property lending, home equity lines of credit, construction and land/lots, indirect auto finance, and consumer lending; and commercial loans, including commercial real estate lending, construction and development lending, and commercial and industrial loans. It also provides ground and equipment lease financing to fire departments. As of June 30, 2017, the company operated 42 offices in North Carolina, Upstate South Carolina, East Tennessee, and Southwest Virginia. HomeTrust Bancshares, Inc. was founded in 1926 and is headquartered in Asheville, North Carolina.

This Rare-Disease Biotech Scores an Important Win

After the FDA approved Palynziq (formerly pegvaliase) for use in adults with phenylketonuria (PKU), a rare genetic disease, this week,�BioMarin Pharmaceutical�(NASDAQ:BMRN)�is in a great position to add hundreds of millions of dollars in new revenue to its top line. BioMarin already markets one PKU therapy, Kuvan, so it should be able to hit the ground running. Is BioMarin a stock worth buying now?

What is PKU?

A genetic disease caused by an inability to break down an amino acid, PKU can result in the toxic buildup of phenylalanine in the brain, particularly if patients consume�protein-rich foods or foods containing aspartame, an artificial sweetener.

IMAGE SOURCE: GETTY IMAGES.

As phenyalanine levels increase to dangerous levels, it can cause irreversible brain damage, developmental delays, and neurological problems, including seizure. It's a severe condition, but it's relatively rare. Globally, it impacts about 50,000 people.�

Because PKU is debilitating, all 50 states in the U.S. require PKU screening at birth. There's no cure for PKU, so treatment involves a lifelong dietary restriction that's very hard for patients to comply with. In�some PKU patients,�BioMarin's Kuvan, a pharmaceutical version of BH4, a natural substance that reduces phenyalanine levels by breaking it down, is also prescribed.

Currently, only about 12% of PKU patients, most of whom are children, take Kuvan, yet it's BioMarin's second best-selling product, with $408 million in sales in 2017.

Reaching more PKU patients

Palynziq is a potent drug, and because of this, it's initially only being approved for use in adults with PKU. BioMarin believes roughly 12,000 adults in the U.S. could benefit from using its newly approved drug and that its worldwide addressable market totals about 33,000 people.�

An enzyme replacement approach, Palynziq substitutes the deficient phenylalanine enzyme in PKU with a version of the enzyme phenylalanine ammonia lyase, which can break down�phenyalanine.�

Immune responses, including anaphylaxis, occurred in Palynziq's trials, so the FDA approval includes a REMS program, and the dosing of it in patients will be titrated over four to six months to improve tolerability and so that patients can take the lowest effective dose. In trials, 11% of patients discontinued Palynziq because of adverse reactions.�

While safety concerns can't be ignored, Palynziq is a first-of-its-kind solution for adult patients, and its efficacy could allow BioMarin to treat substantially more PKU patients than Kuvan. According to BioMarin's management, Palynziq has billion-dollar per year peak sales potential.

Initially, BioMarin's focus will be converting the 200 adult PKU patients that participated in Palynziq's trials into commercial users. Once that's done, the company will focus on the 2,300 adult Americans who are being treated in clinics, and then, it will embrace a strategy to reach the roughly 7,500 patients who are diagnosed with PKU, but who haven't sought out treatment at a clinic for at least two years.

BioMarin expects that Palynziq will be available commercially in late June at an average expected cost of $192,000 per patient per year. At that price, the company would generate $38.4 million in annual sales if it converts the 200 trial participants into regular patients and $480 million per year if it also successfully gets Palynziq prescribed to the 2,300 people being treated in clinics.�

Pricing isn't likely to be as high outside of the U.S., but the addressable market there is bigger, so an EU approval would also be meaningful.�EU regulators accepted Palynziq's application for approval earlier this year, and overall, management says there are 15,000 adult PKU patients in Europe and Turkey, including 4,900 who are being treated in clinics.

What's on deck

Kuvan's use in children should continue to make it a top-seller for the company, at least until generics become available. BioMarin has licensed rights to two generic drugmakers, and generic Kuvan could arrive�as soon as October 2020.

In the meantime, BioMarin will enjoy a dominant position in PKU that will help BioMarin take another step toward achieving profitability. Following Palynziq's OK, BioMarin has now won approvals for seven drugs. In 2017, the company's global revenue was $1.3 billion, so the potential to add hundreds of millions of dollars in new sales would significantly move the needle.�

BMRN Revenue (Annual) data by YCharts.

In addition to improving progress toward profit, the additional revenue will also come in handy in support of BioMarin's R&D pipeline, including a potentially game-changing PKU gene therapy.�BioMarin hopes to begin human trials for a gene therapy that could restore the production of the missing enzyme in PKU patients in 2019.�The potential for a one-and-done gene therapy in PKU would significantly disrupt the market.

Overall, the impact Palynziq may have on BioMarin's financials in the next year or two, and the opportunity longer-term to create even better treatments for PKU, make it an interesting stock that I think is worth buying in growth portfolios.

This Day In Market History: NYSE Starts Disclosing Short Sales

Each day, Benzinga takes a look back at a notable market-related moment that occurred on this date.

What Happened?

On this day 87 years ago, the New York Stock Exchange began regularly reporting short selling data for the first time.

Where The Market Was

The Dow finished the day at 132.87. The S&P 500 traded at around 13.80. Today, the Dow is trading at 24,811.76 and the S&P 500 is trading at 2,727.76.

What Else Was Going On In The World?

In 1931, the Empire State Building opened its doors in New York, and unemployment in the U.S. doubled to 16.3 percent as the Great Depression set in. A loaf of bread cost 8 cents.

Short Sellers Come Out Of The Shadows

The Dow dropped 32.6 percent in 1930 as the American economy took a nosedive, but short sellers in the stock market made a killing. Short sellers took a lot of heat for the stock market crash of 1929, which led to the enactment of the uptick rule shortly thereafter. The uptick rule requires short selling orders to be filled only during upticks in share prices and is meant to mitigate the negative impact of short sales. The uptick rule was abolished in 2007 just prior to the market crash of 2008.

In May 1931, the NYSE made the decision to regularly disclose short sale data for the first time so traders could know just how much money was being bet against the market.

Today, traders routinely use short-selling-related metrics such as short volume, short interest, utilization rate and short percent of float to help inform trading decisions.

Related Links:

This Day In Market History: AOL Is Founded

Inogen Hit By Citron Report; Analyst Rebuttal Calls This 'An Excellent Entry Point'

Photo by Thomas J. O'Halloran via the Library of Congress. 

Best China Stocks To Buy For 2018

tags:ENV,NWL,MGK,CCU,RBCN,STNG,

The U.S. has a new bargaining chip on the table when it comes to Iranian sanctions: Shale.

In 2012, American oil stayed on American shores, giving the U.S. less leverage to compel powerhouse oil-consuming countries like India and China to sanction Iran. That was then, this is now. The crude export ban is lifted, and “the U.S. is as large of an exporter as Iran -- 2.5 million barrels a day,” Jeff Currie, Goldman Sachs Group Inc’s global head of commodities, said Thursday in an interview with Bloomberg TV.

“That now gives them a bargaining chip -- saying -- ‘Hey, if you don’t comply, we can take away those barrels,’” he said. “It is a way to enforce compliance on refiners around the world.”

Sanctions on Iran will reduce the Islamic Republic’s ability to produce and export, but the lost oil supply will be supplanted by allies of the U.S., like Saudi Arabia, Currie said. While there is “a lot of geopolitical stuff going on,” the current oil rally is underpinned by real demand, not the headlines, he said.

Best China Stocks To Buy For 2018: Envestnet, Inc(ENV)

Advisors' Opinion:

• [By Dan Caplinger]

  Financial services companies rely on the health of the markets to bring them business from the large institutions that are their best customers. With a bull market that's almost a decade long at this point, Wall Street has never been stronger, and that's given a big boost to financial information technology specialist Envestnet (NYSE:ENV). Yet as volatility returns to the stock market in early 2018, some investors feared that Envestnet's time in the sun might soon end and give way to more difficult conditions looking ahead.

• [By Stephan Byrd]

  Zillow (NASDAQ: ZG) and Envestnet (NYSE:ENV) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Best China Stocks To Buy For 2018: Newell Rubbermaid Inc.(NWL)

Advisors' Opinion:

• [By ]

  Starboard Value's Jeff Smith on Wednesday officially launched a boardroom battle at Newell Brands Inc. (NWL) , offering up a minority-slate of four candidates that will partly go up against directors recently installed by rival billionaire insurgent Carl Icahn, in a skirmish over which activist fund will be better able to oversee $10 billion worth of asset sales at the Mr. Coffee maker.

• [By ]

  Not every battle is worth fighting, Cramer told viewers. That's especially true if you own shares of Newell Brands (NWL) , which is embroiled in a bitter proxy fight between activists Starboard Capital and Carl Icahn.

• [By ]

  Not every battle is worth fighting, Cramer told viewers. That's especially true if you own shares of Newell Brands (NWL) , which is embroiled in a bitter proxy fight between activists Starboard Capital and Carl Icahn.

• [By Lisa Levin] Gainers Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 34.7 percent to $45.50 in pre-market trading following news that the FDA has approved Andexxa for the reversal of factor Xa inhibitors. Euro Tech Holdings Company Limited (NASDAQ: CLWT) rose 15.7 percent to $6.65 in pre-market trading after climbing 155.56 percent on Thursday. China Recycling Energy Corporation (NASDAQ: CREG) rose 14.7 percent to $2.75 in pre-market trading after climbing 57.89 percent on Thursday. Pandora Media, Inc. (NYSE: P) rose 11 percent to $6.40 in pre-market trading after reporting strong quarterly results. Fred's, Inc. (NASDAQ: FRED) rose 9.2 percent to $1.90 in pre-market trading following Q4 results. Shake Shack Inc (NYSE: SHAK) rose 9.1 percent to $51.70 in pre-market trading after the company reported upbeat results for its first quarter and raised its FY18 guidance. Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) rose 9 percent to $12.55 in pre-market trading after the company posted Q1 results and agreed to acquire HealthGrid. Weight Watchers International, Inc. (NYSE: WTW) rose 7.6 percent to $75 in pre-market trading after the company reported stronger-than-expected results for its first quarter. The company also raised its FY18 earnings outlook from $2.40-$2.70 to $3-$3.20. Viavi Solutions Inc. (NASDAQ: VIAV) rose 7.5 percent to $10.15 in pre-market trading following Q3 results. Pearson plc (NYSE: PSO) rose 4.5 percent to $11.83 in pre-market trading after reporting strong quarterly earnings. Alibaba Group Holding Ltd (NYSE: BABA) shares rose 4.4 percent to $190.50 in the pre-market trading session as the company posted upbeat Q4 results. Aqua Metals, Inc. (NASDAQ: AQMS) shares rose 3.9 percent to $4.30 in pre-market trading after gaining 6.98 percent on Thursday. Newell Brands Inc (NYSE: NWL) shares rose 3.6 percent to $27.65 in pre-market trading after reporting upbeat quarterly earnings. HMS Holdings Corp (NASDAQ: H

Best China Stocks To Buy For 2018: Vanguard Mega Cap Growth ETF (MGK)

Advisors' Opinion:

• [By Ethan Ryder]

  Fernwood Investment Management LLC lessened its stake in VANGUARD MEGA CAP 300 GROWTH ETF (BMV:MGK) by 9.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,022 shares of the company’s stock after selling 1,698 shares during the period. VANGUARD MEGA CAP 300 GROWTH ETF comprises 1.1% of Fernwood Investment Management LLC’s portfolio, making the stock its 26th biggest holding. Fernwood Investment Management LLC owned approximately 0.06% of VANGUARD MEGA CAP 300 GROWTH ETF worth $1,911,000 as of its most recent filing with the SEC.

Best China Stocks To Buy For 2018: Compania Cervecerias Unidas, S.A.(CCU)

Advisors' Opinion:

• [By Dan Caplinger]

  Beverage stocks have been a hit-or-miss proposition in the U.S., both for megabrewers and for smaller players in the craft beer, spirits, and soft drink industries. But there are plenty of opportunities internationally to invest in the companies that produce drinks. In Chile, Compania Cervecerias Unidas (NYSE:CCU) produces beer, wine, and soft drinks for several South American countries, and after having seen a slow period to finish 2017, CCU had hoped to find ways to bounce back to start the new year.

Best China Stocks To Buy For 2018: Rubicon Technology, Inc.(RBCN)

Advisors' Opinion:

• [By Logan Wallace]

  Rubicon Technology (NASDAQ:RBCN) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday.

Best China Stocks To Buy For 2018: Scorpio Tankers Inc.(STNG)

Advisors' Opinion:

• [By Max Byerly]

  Get a free copy of the Zacks research report on Scorpio Tankers (STNG)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Rich Smith]

  Stocks don't always make sense -- a fact�investors should be happy about after�Scorpio Tankers (NYSE:STNG) posted a quarterly loss and an earnings miss this morning and then rocketed 15% in early trading.

• [By Lisa Levin]

  Wednesday afternoon, the energy shares gained 0.74 percent. Meanwhile, top gainers in the sector included Pengrowth Energy Corporation (NYSE: PGH), up 12 percent, and Scorpio Tankers Inc. (NYSE: STNG), up 12 percent.

• [By Lisa Levin] Gainers Daré Bioscience, Inc. (NASDAQ: DARE) shares jumped 56.69 percent to close at $1.27 on Wednesday on news that the company entered into worldwide license agreement for Juniper Pharmaceuticals' intravaginal ring technology platform. Vicor Corporation (NASDAQ: VICR) rose 26.84 percent to close at $37.10. Vicor posted Q1 earnings of $0.10 per share on sales of $65.2 million. AGM Group Holdings Inc. (NASDAQ: AGMH) climbed 25.56 percent to close at $10.61. Travelzoo (NASDAQ: TZOO) gained 24.7 percent to close at $9.75 following strong Q1 results. Intrepid Potash, Inc. (NYSE: IPI) shares climbed 19.24 percent to close at $4.71. China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 18.73 percent to close at $18.64. Genprex, Inc. (NASDAQ: GNPX) climbed 18.28 percent to close at $5.89. Genprex expanded its operations to Cambridge, Mass. Scorpio Tankers Inc. (NYSE: STNG) rose 13.92 percent to close at $2.70 following Q1 results. Rocky Brands, Inc. (NASDAQ: RCKY) shares surged 13.57 percent to close at $23.85 after reporting Q1 results. Resonant Inc. (NASDAQ: RESN) shares rose 12.5 percent to close at $4.14 on Wednesday. USANA Health Sciences, Inc. (NYSE: USNA) jumped 11.24 percent to close at $106.85 following Q1 results. SUPERVALU Inc. (NYSE: SVU) rose 11.16 percent to close at $16.24 after the company reported Q4 results and agreed to sell and leaseback eight distribution centers for an aggregate purchase price of $483 million. K12 Inc. (NYSE: LRN) shares gained 10.74 percent to close at $15.36 following Q3 results. Tupperware Brands Corporation (NYSE: TUP) rose 9.15 percent to close at $46.28 as the company posted in-line quarterly earnings. Six Flags Entertainment Corporation (NYSE: SIX) shares climbed 8.49 percent to close at $64.18 as the company posted a narrower-than-expected loss for its first quarter. Carlisle Companies Incorporated (NYSE: CSL) gained 8.2 percent to close at $107.94 af